222 related articles for article (PubMed ID: 36873929)
1. Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.
Tong A; Di X; Zhao X; Liang X
Front Genet; 2023; 14():952379. PubMed ID: 36873929
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
[TBL] [Abstract][Full Text] [Related]
3. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
4. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
5. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
6. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
[TBL] [Abstract][Full Text] [Related]
7. Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma.
Zheng M; Hu Y; Gou R; Wang J; Nie X; Li X; Liu Q; Liu J; Lin B
Aging (Albany NY); 2019 Jun; 11(12):4198-4215. PubMed ID: 31257224
[TBL] [Abstract][Full Text] [Related]
8. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
[TBL] [Abstract][Full Text] [Related]
9. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
10. Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
Zhu C; Xu Z; Zhang T; Qian L; Xiao W; Wei H; Jin T; Zhou Y
J Cancer; 2021; 12(8):2295-2316. PubMed ID: 33758607
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
12. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
13. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
Yamaguchi K; Mandai M; Oura T; Matsumura N; Hamanishi J; Baba T; Matsui S; Murphy SK; Konishi I
Oncogene; 2010 Mar; 29(12):1741-52. PubMed ID: 20062075
[TBL] [Abstract][Full Text] [Related]
14. Treatment issues in clear cell carcinoma of the ovary: a different entity?
Pectasides D; Pectasides E; Psyrri A; Economopoulos T
Oncologist; 2006; 11(10):1089-94. PubMed ID: 17110628
[TBL] [Abstract][Full Text] [Related]
15. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Chromatin Remodeling Genes and the Rho GTPases
Arildsen NS; Jönsson JM; Bartuma K; Ebbesson A; Westbom-Fremer S; Måsbäck A; Malander S; Nilbert M; Hedenfalk IA
Front Oncol; 2017; 7():109. PubMed ID: 28611940
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
18. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
19. Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea.
Kim SI; Ha HI; Eoh KJ; Lim J; Won YJ; Lim MC
Front Oncol; 2022; 12():874037. PubMed ID: 35463304
[TBL] [Abstract][Full Text] [Related]
20. Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.
Wu J; You Y; Zhuang R; Guo X; Zhang C; Zhang Q; Zhou Y; Li Q
Ann Transl Med; 2022 Mar; 10(6):387. PubMed ID: 35433993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
